François Jacob Institute of biology - On the same theme https://jacob.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2015/Modulating-cerebral-cholesterol-new-avenue-research-treat-Alzheimer.aspx Website of the François Jacob Institute of Biology en-US https://jacob.cea.fr/drf/ifrancoisjacob/SiteAssets/logo-cea-JACOB.png François Jacob Institute of biology - On the same theme https://jacob.cea.fr/drf/ifrancoisjacob/english An Alzheimer's model to study the propagation of the pathological forms of tau https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2023/Alzheimer-propagation-forms-pathological-Tau-.aspx In an article published in Neurobiology of Disease, researchers from MIRCen's Neurodegenerative Diseases Laboratory present a novel model of Alzheimer's disease that enables the study of tauopathy inter-neuronal propagation mechanisms, the identification of new therapeutic targets and the exploration of new treatments. Neurodegenerative diseases ; Alzheimer's disease ; Cellular mechanisms Researchers ; general public ; Journalists MIRcen Highlight ; Scientific result Alzheimer Disease;Cellular biology;tau protein;AAV; Fri, 16 Jun 2023 10:00:00 GMT LMN/MIRCen team wins "Équipe FRM 2023" accreditation https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Other-News/2023/lmn-mircen-frm-team.aspx Carole Escartin's Reactive Astrocytes team (UMR9199, Neurodegenerative Diseases Laboratory, MIRCen) has received the Équipe FRM 2023 label for its project on the role of astrocytes in the control of neuronal activity. Institutional ; Fundamental Research ; Brain ; Diagnosis and innovative treatment ; Gene and cell therapy ; Alzheimer's disease Researchers ; Journalists ; general public DRF Live in the center ; Highlight astrocytes;Alzheimer's Disease; Wed, 29 Mar 2023 10:00:00 GMT Beta thalassemia: toward a more effective therapeutic strategy https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2021/beta-thalassemia-more-effective-therapeutic-strategy.aspx In a study published in Molecular Therapy, LCSAT (IDMIT, CEA-Jacob) researchers present a novel, optimized, lentiviral gene therapy for β-thalassemia. Gene and cell therapy Researchers ; general public ; Journalists STI Scientific result ; Highlight lentiglobin;lentiviral gene therapy;beta-thalassemia;he; Thu, 20 May 2021 10:00:00 GMT Lucile Ben Haïm wins support from Vaincre Alzheimer https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Other-News/2021/Lucile-Ben-Haim-wins-support-from-Vaincre-Alzheimer.aspx Every year, the foundation Vaincre Alzheimer lends its support to promising projects in the battle against Alzheimer's disease. Among the six chosen this year is that of Lucile Ben Haïm of the Neurodegenerative Diseases Laboratory (MIRCen/CEA-Jacob). Her project involves targeting astrocytes to treat depression symptoms associated with this progressive neurological disorder. Alzheimer's disease Researchers ; Journalists ; general public Live in the center astrocyte;Alzheimer;Depression;reactive astrocytes; Wed, 17 Feb 2021 11:00:00 GMT Stealthy agents in Alzheimer's disease https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2020/Stealthy-agents-Alzheimer-disease.aspx Researchers from MIRCen (CEA-Jacob) have shown that undetectable proteinaceous aggregates involved in Alzheimer's disease can be transmitted during brain surgeries in an experimental context. Brain ; Neurodegenerative diseases ; Alzheimer's disease Researchers ; general public ; Journalists MIRcen Scientific result ; Highlight amyloid deposits;Alzheimer Disease;transmission;neurodegenerative diseases; Wed, 09 Dec 2020 11:00:00 GMT Anti-HIV antibodies: predicting in vivo efficacy in vitro https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2020/Anti-HIV-antibodies-predicting-in-vivo-efficacy-in-vitro.aspx A study performed by an IDMIT team (CEA-Jacob) has resulted in an in vitro approach for predicting the in vivo efficacy of antibodies used for the prevention of HIV-1 transmission. The work identified antibodies capable of efficaciously blocking intercellular viral transmission in infected semen. Vaccine ; AIDS ; Infectious diseases ; Diagnosis and innovative treatment ; Biotechnology ; Virus Researchers ; general public ; Journalists IDMIT Scientific result ; Highlight intercellular transmission;sperm;vaccine;Antibody;HIV;AIDS; Fri, 07 Aug 2020 10:00:00 GMT Molecular chaperones and tauopathies: a double-edged sword https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2020/Molecular- chaperones-tauopathies-double-edged-sword.aspx As part of an international study published in The Journal of Biological Chemistry, a team from LMN (MIRCen/CEA-Jacob) discovered an unexpected mechanism involving chaperone proteins in Tau disassembly. Neurodegenerative diseases ; Alzheimer's disease general public ; Journalists ; Researchers MIRcen Scientific result ; Highlight molecular chaperones;Alzheimer;tauopathies;neurodegenerative diseases; Fri, 17 Jul 2020 10:00:00 GMT Alzheimer's and Parkinson's diseases: infectious proteinopathies capture the attention of academicians https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Other-News/2020/infectious-proteinopathies-capture-attention-of-academicians.aspx At a joint meeting of the French Academies of Medicine and Pharmacy held 19 November 2019, Ronald Melki of the Neurodegenerative Diseases Laboratory (MIRCen/CEA-Jacob) gave a descriptive review of experimental elements enabling a better understanding of infectious proteinopathy in Alzheimer's and Parkinson's diseases. Alzheimer's disease ; Parkinson's disease ; Neurodegenerative diseases Journalists ; general public ; Researchers DRF News Alzheimer Disease;aggregation;abnormal Tau protein aggregates;Alzheimer;neurodegenerative diseases;Parkinson;tauopathies;Parkinson's disease; Sun, 05 Jul 2020 10:00:00 GMT Medical Research Foundation: 'mini-brains' to help Alzheimer's disease research https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Other-News/2020/Medical-Research-Foundation-mini-brains-to-help-Alzheimer-disease-research.aspx The FRM has just selected eight research projects in its call for projects on the fundamental mechanisms of Alzheimer's disease. A financial contribution of up to 600,000 euros has been allocated to fund the salaries, equipment and operating costs for each project for a period of 2 to 3 years. Among the funded projects, a project led by SEPIA (CEA-Jacob), Genoscope (CEA-Jacob) and ENS-Saclay, focuses on the use of cerebral organoids or 'mini-brains' as a model for the study of Alzheimer's disease. Alzheimer's disease ; Neurodegenerative diseases Researchers ; Journalists DRF Highlight ; News Alzheimer Disease;cerebral organoïds;neurodegenerative diseases; Mon, 30 Mar 2020 10:00:00 GMT Alzheimer: an amino acid to the rescue of astrocyte metabolism https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2020/Alzheimer-an-amino-acid-to-the-rescue-of-astrocyte-metabolism.aspx Scientists from the Laboratory of Neurodegenerative Diseases (MIRCen/ François Jacob Institute of Biology) in collaboration with the Neurocentre Magendie (Inserm/University of Bordeaux) have highlighted the decisive role played by a metabolic pathway in memory disorders in Alzheimer's disease. Their work, published in Cell Metabolism, also shows that L-serine intake, in the form of a dietary supplement, restores the spatial memory that is affected early on in mouse models of the disease. Neurodegenerative diseases ; Alzheimer's disease Researchers ; Journalists DRF Highlight ; Scientific result ; News Alzheimer;L-serine;astrocytes;Brain;neurodegenerative diseases; Tue, 03 Mar 2020 11:00:00 GMT New knowledge for cell therapies in neurodegenerative diseases https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2019/New-knowledge-for-cell-therapies-in-neurodegenerative-diseases.aspx MIRCen contributed to a study that showed that the use of histocompatible neuronal grafts did not eliminate the need for immunosuppressive drugs in a primate model. Those results provide important knowledge for the clinical use of certain cell therapies under development for the treatment of neurodegenerative diseases. Brain ; Neurodegenerative diseases ; Gene and cell therapy Scientific result Wed, 09 Oct 2019 10:00:00 GMT Neurodegeneration may be induced by brains of Alzheimer patients https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2019/Neurodegeneration-may-be-induced-by-brains-of-Alzheimer-patients.aspx MIRCen researchers have shown that the intracerebral injection of Alzheimer brain extracts into a primate induces lesions typical of the disease and neurodegenerative processes associated with memory loss. Brain ; Neurodegenerative diseases ; Alzheimer's disease Scientific result Mon, 16 Sep 2019 10:00:00 GMT A new generation of lentivirus for gene therapy https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2019/A-new-generation-of-lentivirus-for-gene-therapy.aspx Researchers from STI have developed a new generation of lentivirus, paving the way for the use of Mauritian cynomolgus macaque as a pre-clinical study model for the development of new gene therapy products. Health & life sciences ; Gene and cell therapy Researchers ; Journalists STI Highlight ; Scientific result DNA;Gene and cell therapy;pre-clinical; Mon, 22 Jul 2019 10:00:00 GMT "Mini-brains" for research on Alzheimer's disease https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2019/mini-brains-research-Alzheimer-disease.aspx A partnership between the François Jacob Institute of Biology/CEA, The Frédéric Joliot Institute for Life Sciences/CEA and CellTechs (a Sup'Biotech lab) has led to a new approach for modeling Alzheimer's disease in vitro. Health & life sciences ; Brain ; Alzheimer's disease MIRcen Scientific result Brain;Alzheimer; Mon, 14 Jan 2019 11:00:00 GMT Alzheimer’s: identification of potential target protein aggregates for treating the disease https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Press/2019/alzheimer-identification-potential-target-protein-aggregates-disease.aspx The propagation of tau protein aggregates in the brain contributes to the progression of Alzheimer’s disease. Researchers at the Neurodegenerative Diseases Laboratory: mechanisms, therapies, imaging (CNRS/CEA/Université Paris-Sud, MIRCen), working in collaboration with the Ecole Normale Supérieure, Sorbonne University and Inserm, have just identified the targets of these aggregates. Alzheimer's disease ; Brain ; Health & life sciences general public ; Institutions ; Journalists ; Researchers ; Higher education DRF Press release CNRS;inserm; Thu, 10 Jan 2019 11:00:00 GMT Alzheimer's disease: blocking reactive astrocytes to help neurons https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2018/Alzheimer-disease-blocking-reactive-astrocytes-help-neurons.aspx Researchers from MIRCen have shown that inhibiting reactive astrocytes is beneficial for certain characteristics of Alzheimer's disease. Their results could lead to novel therapies that act upon astrocytes to improve neuron function. Brain ; Gene and cell therapy ; Alzheimer's disease ; Cellular mechanisms Paris-Saclay Scientific result Alzheimer;astrocytes;neuron; Mon, 29 Oct 2018 11:00:00 GMT A new success in gene therapy for beta thalassemia https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2018/New-success-in-gene-therapy-for-beta-thalassemia.aspx ​The efficacy of a gene therapy developed at the François Jacob Institute of Biology and Harvard University has been demonstrated in phase I/II clinical trials. Gene and cell therapy ; Genetic diseases Scientific result ; Press release Thu, 19 Apr 2018 10:00:00 GMT A summertime reduction in the plasma level of a peptide association with Alzheimer's disease https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2018/summertime-reduction-plasmatic-amyloid-alzheimer.aspx Researchers from MIRCen have brought to light a reduction in the amount of an amyloid beta peptide associated with Alzheimer's disease in the plasma of a primate model during the summer season. Alzheimer's disease Fontenay-aux-Roses Scientific result Amyloid; Fri, 23 Mar 2018 11:00:00 GMT Neurofibrillary tangles: a protective role in Alzheimer's disease? https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2018/neurofibrillary-tangles-protective-role-alzheimer.aspx Neurofibrillary tangles are large aggregates of tau protein found in the neurons of people with Alzheimer's disease. Historically, they have been thought to be at least partially responsible for the pathology. However, the results of a study performed by researchers at MIRCen (François Jacob Institute of Biology/CEA) suggest to the contrary that neurofibrillary tangles may be protective. Alzheimer's disease ; Molecular mechanisms Fontenay-aux-Roses Scientific result neurofibrillary tangles;tau protein;hyperphosphorylation; Thu, 08 Mar 2018 11:00:00 GMT NeurATRIS : Call for collaborative projects on neurodegenerative diseases https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Other-News/2018/Neuratris-call.aspx ​NeurATRIS lance un appel à projets pour initier des projets collaboratifs entre les membres de NeurATRIS, les laboratoires académiques et les sociétés de biotechnologies. A la clé, un financement à hauteur de 50K€. Diagnosis and innovative treatment ; Gene and cell therapy ; Neurodegenerative diseases News ; Academic partnerships ; Industrial partnerships Thu, 18 Jan 2018 11:00:00 GMT Hemoglobinopathies: a gene therapy modifies 100% of targeted cells https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2017/Hemoglobinopathies-amelioration-therapie-genique.aspx ​The researchers at the François Jacob Institute's Department of Innovative Therapies are pursuing the development of their gene therapy for hereditary blood diseases. They are looking to increase the performance of their strategy so that it can bring benefits to the greatest number of patients possible. Genetic diseases ; Gene and cell therapy STI Scientific result Thu, 21 Dec 2017 11:00:00 GMT Alzheimer's disease: a novel animal model https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2017/Alzheimer-novel-animal-model.aspx A new animal model expresses the two biological characteristics of Alzheimer's disease, enabling new possibilities for treatment assessment and simplified diagnosis. Simulation & modelling ; Alzheimer's disease Researchers ; general public ; Journalists Fontenay-aux-Roses Scientific result Fri, 20 Oct 2017 10:00:00 GMT Sickle cell disease: remission of the signs of the disease in the first patient in the world treated with gene therapy https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Press/2017/Sickle-cell-disease-remission-signs-disease-first-patient-treated-gene-therapy.aspx A patient aged of 13 years with severe sickle cell disease has been treated succesfully by a gene therapy. This innovative treatment allowed complete remission of clinical signs of disease and correction of biological signs. Gene and cell therapy ; Genetic diseases ; Diagnosis and innovative treatment ; Health & life sciences general public ; Journalists ; Researchers Paris-Saclay Press release ; Scientific publications sickle cell anemia;Diagnosis and innovative treatment;Genetic diseases;Gene and cell therapy;Health & life sciences; Thu, 02 Mar 2017 00:00:00 GMT Chronic Myeloid Leukemia: a New Therapy Proves Successful https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2017/Chronic-Myeloid-Leukemia-a-New-Therapy-Proves-Successful.aspx In a phase 2 clinical trial, scientists showed the efficiency of targeting cancer stem cells—an approach imagined and developed at the CEA François-Jacob Institute for the treatment of leukemia, chronic myeloid leukemia in particular. Cancer ; Gene and cell therapy general public ; Journalists ; Researchers Jacob Scientific result Tue, 28 Feb 2017 11:00:00 GMT Modulating cerebral cholesterol: a new avenue of research to treat Alzheimer’s disease? https://www.cea.fr/drf/ifrancoisjacob/english/Pages/News/Scientific-News/2015/Modulating-cerebral-cholesterol-new-avenue-research-treat-Alzheimer.aspx Two French research teams have recently shown in a rodent model that overexpression of an enzyme capable of eliminating excess cholesterol in the brain can act in a beneficial way on the tau component of the disease to completely correct it. Alzheimer's disease ; Gene and cell therapy ; Biotechnology MIRcen Scientific result Mon, 14 Sep 2015 10:00:00 GMT